APAC Alzheimer’s Disease Market

APAC Alzheimer's Disease Market Size (2024 to 2029)

The size of the Asia Pacific Alzheimer's disease market was worth USD  2958.04 Million in 2024 and is estimated to be growing at a CAGR of 5.39% to reach USD 3835.93 Million by 2029.

The aging population is a primary driver of the market for Alzheimer's in the APAC region.

Rising life expectancy contributes to rapid rises in the number of older people and the prevalence of chronic diseases such as dementia. Treatments for Alzheimer's disease provide only transient and unreliable benefits for people's well-being, and none of the approved medications can alter the illness's progression. As a result of the size of the affected population and the lack of appropriate and effective treatment, pharmacy producers have a huge opportunity. Increased pipeline drug research, investment in biomarkers for drug development, and better diagnostics for early detection are all propelling this market forward. However, due to rigorous rules, drug producers have been unable to demonstrate significant therapeutic benefits of treatment for several novel substances. Collaboration between current players is one of the most notable trends. Specifically, diagnostic technology companies are working diligently to develop effective biomarker technologies to support and improve drug development for new medication candidates, which are projected to drive higher demand.

The APAC Alzheimer's disease market expansion is expected to be hampered by strict requirements for medication development and clinical trials. The high expense of medications used to treat Alzheimer's disease also plays a role. Furthermore, the shortage of qualified medical practitioners in underdeveloped countries impedes the growth of the Alzheimer's disease treatments and diagnostics market. In addition, the Alzheimer's disease therapeutics and diagnostics market has had a substantial growth hurdle throughout the projection period due to a lack of understanding about novel treatments used to treat the condition.

This research report on the Asia Pacific Alzheimer's disease market has been segmented & sub-segmented into the following categories

APAC Alzheimer's Disease Market Analysis By Therapeutics

• Marketed Drugs

  • NMDA Receptor Antagonists

  • Cholinesterase Inhibitors
• Pipeline Drugs

APAC Alzheimer's Disease Market Analysis By Diagnostics

• Computed Tomography Scan
• Electroencephalography
• Lumbar Puncture Test
• Magnetic Resonance Imaging
• Positron Emission Tomography
• Others

APAC Alzheimer's Disease Market Analysis By Country

• India

• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, Asia-Pacific is the fastest-growing market for Alzheimer's disease. The key driver of the Alzheimer's disease pharmaceuticals and diagnostics market in China is Alzheimer's rapidly growing population, resulting in a growing elderly population. As a result of the aging population's vulnerability to diseases like dementia, dementia is becoming more prevalent, particularly in semi-urban and rural areas. According to the Ministry of Health, China is one of the leading countries in terms of the number of people affected by dementia, accounting for almost 20% of all dementia cases worldwide. This market is predicted to grow at the fastest rate during the forecast period, owing to an increase in the aging population in Asia Pacific's growing regions. For this market, developing countries are likely to provide attractive potential. According to Alzheimer's disease International, 59 percent of dementia patients lived in developing nations in 2015; however, this number is expected to climb to 69 percent by 2050. China, India, and their south Asian and western Pacific neighbors have the fastest-growing elderly populations.

KEY MARKET PLAYERS

Companies playing a notable role in the APAC Alzheimer's Disease market in this region are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals, etc.